



***Powering
Digestion***



Creon®: #1 Dispensed Pancreatic Enzyme in Canada^{1*}

Creon Minimicrospheres® (pancreatin) is indicated in pediatric and adult patients for:

- Treatment of pancreatic exocrine insufficiency (PEI) attributed to: cystic fibrosis, chronic pancreatitis or any other medically defined pancreatic disease that might require pancreatic enzyme therapy

Pancreatic Exocrine Insufficiency (PEI) is the failure of the pancreas to produce an adequate level of digestive enzymes, resulting in the inability to properly digest food.²⁻⁴

Have you ruled out PEI? It may be more common than you think.

Symptoms can include:⁵

- Abdominal pain
- Weight loss in adults
- Flatulence
- Loose stools
- Steatorrhea (greasy, foul-smelling stools)

When digestion is not adequate due to PEI, think Creon Minimicrospheres^{®5}

Creon[®] offers a range of strengths for individualized dosing of pancreatic enzyme replacement therapy in PEI.⁵

Creon Minimicrospheres[®] Micro:

5,000 Ph.Eur.U lipase
5,100 Ph.Eur.U amylase
320 Ph.Eur.U protease

Creon Minimicrospheres[®] 10:

10,000 Ph.Eur.U lipase
11,200 Ph.Eur.U amylase
730 Ph.Eur.U protease

Creon Minimicrospheres[®] 25:

25,000 Ph.Eur.U lipase
25,500 Ph.Eur.U amylase
1,600 Ph.Eur.U protease

Creon Minimicrospheres[®] should be adjusted according to the **severity of PEI, minimization of steatorrhea and maintenance of good nutritional status.**⁵

*Comparative clinical significance has not been established

Consult the Product Monograph at <http://www.mylan.ca> for more information about:

- Contraindications in patients with: known hypersensitivity to porcine protein or pancreatic enzymes
- The most serious warnings and precautions regarding: fibrosing colonopathy and substitution with other pancreatic enzyme products
- Other relevant warnings and precautions regarding: adequate hydration; change in pancreatin dose or brand; potential viral exposure from the product source; hyperuricosuria and hyperuricemia; use during pregnancy or breastfeeding
- Conditions of clinical use, adverse reactions, drug interactions and dosing instructions

The Product Monograph is also available by calling Mylan at 1-844-596-9526.

® Registered trademarks of BGP Products Operations GmbH. Licensed use by BGP Pharma ULC, a Mylan company.

References:

1. Data on file [IMS HEALTH data], BGP Pharma ULC. August 2017.
2. Löhr JM et al. *UEG Journal*. 2013;1(2):79-83.
3. Toouli J et al. *Med J Aust*. 2010;193(8):461-7.
4. Sikkens ECM et al. *Best Pract Res Clin Gastroenterol*. 2010;24(3):337-47.
5. Creon Minimicrospheres® Product Monograph. BGP Pharma ULC. January 8, 2016.



© Mylan 2019. All rights reserved.
85 Advance Road, Etobicoke, Ontario, M8Z 2S6

www.mylan.ca
1-844-596-9526

CRE-2019-0020E - FE2019

Creon Minimicrospheres® dosing should be adjusted according to the severity of the pancreatic enzyme deficiency.⁵

Adult dosing recommendations for conditions other than cystic fibrosis

Dose range for meals

25,000 to 80,000
units of lipase

Dose range for snacks

12,500 to 40,000
units of lipase
(half of the required meal dose)

- Creon Minimicrospheres® should be individualized according to the degree of maldigestion and the fat content of the meal.⁵
- Creon Minimicrospheres® should be taken with enough fluid during or after each meal or snack.⁵
 - In certain conditions, e.g. acute pancreatitis, Creon® should be taken when food intake has started again.⁵

Unsure how to communicate Creon® to the pharmacist?

Example:

